Guided Therapeutics Inc (GTHP)
GTHP is quoted over the counter, not listed on an exchange. Guided Therapeutics Inc files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | GTHP, quoted over the counter |
| SEC CIK | 0000924515 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Business address | Peachtree Corners, GA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The factors below raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-08-13 |
| Cash and burn | $12K cash; operating cash flow -$376K a quarter. | Report 2026-06-30 |
| Shares outstanding | 96,537,349 (2026-08-07); 80,283,991 a year earlier; 51,288,937 three years earlier. | Cover page 2026-08-07 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | UHY LLP, Sterling Heights, Michigan, United States | PCAOB Form AP 2026-04-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $0 | -$605K | -$319K | $12K | $53K | $650K | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $0 | -$500K | -$617K | $369K | $91K | $767K | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $590K | -$1.2M | -$291K | $63K | $534K | $767K | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | $60K | -$742K | -$277K | $87K | $556K | $178K | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | $117K | -$811K | -$169K | $185K | $445K | $118K | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $0 | -$427K | -$331K | $115K | $35K | $1K | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $1K | -$652K | -$332K | $388K | $270K | $7K | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | $0 | -$654K | -$473K | $194K | No debt tags | $38K | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1 | 2023-01-13 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-03-10 |
| Latest proxy | DEF 14A | 2021-07-06 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier